170 related articles for article (PubMed ID: 11374688)
1. An open trial of octreotide long-acting release in the management of short bowel syndrome.
Nehra V; Camilleri M; Burton D; Oenning L; Kelly DG
Am J Gastroenterol; 2001 May; 96(5):1494-8. PubMed ID: 11374688
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
Penning C; Vecht J; Masclee AA
Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971
[TBL] [Abstract][Full Text] [Related]
3. [The role of long-acting release (LAR) depot octreotide as adjuvant management of short bowel disease].
Gómez-Herrera E; Farías-Llamas OA; Gutiérrez-de la Rosa JL; Hermosillo-Sandoval JM
Cir Cir; 2004; 72(5):379-86. PubMed ID: 15550227
[TBL] [Abstract][Full Text] [Related]
4. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE; Thornton-Jones VA; Wass JA
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[TBL] [Abstract][Full Text] [Related]
5. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
6. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients.
Nikou GC; Toumpanakis C; Katsiari C; Charalambopoulos D; Sfikakis PP
J Clin Rheumatol; 2007 Jun; 13(3):119-23. PubMed ID: 17551375
[TBL] [Abstract][Full Text] [Related]
7. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
Matulonis UA; Seiden MV; Roche M; Krasner C; Fuller AF; Atkinson T; Kornblith A; Penson R
J Pain Symptom Manage; 2005 Dec; 30(6):563-9. PubMed ID: 16376743
[TBL] [Abstract][Full Text] [Related]
8. Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome.
Klooker TK; Kuiken SD; Lei A; Boeckxstaens GE
Aliment Pharmacol Ther; 2007 Aug; 26(4):605-15. PubMed ID: 17661764
[TBL] [Abstract][Full Text] [Related]
9. A prospective within-patient comparison clinical trial on the effect of parenteral cimetidine for improvement of fluid secretion and electrolyte balance in patients with short bowel syndrome.
Kato J; Sakamoto J; Teramukai S; Kojima H; Nakao A
Hepatogastroenterology; 2004; 51(60):1742-6. PubMed ID: 15532817
[TBL] [Abstract][Full Text] [Related]
10. Effect of glutamine in short-bowel syndrome.
Scolapio JS; McGreevy K; Tennyson GS; Burnett OL
Clin Nutr; 2001 Aug; 20(4):319-23. PubMed ID: 11478829
[TBL] [Abstract][Full Text] [Related]
11. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors.
Gregersen T; Grønbæk H; Worsøe J; Schlageter V; Laurberg S; Krogh K
Scand J Gastroenterol; 2011 Jul; 46(7-8):895-902. PubMed ID: 21623673
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
13. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
[TBL] [Abstract][Full Text] [Related]
14. Rheumatoid arthritis associated with the use of Sandostatin® LAR® depot in a patient with pancreatic neuroendocrine tumor. An association or a coincidence? The first case report.
Saif MW
JOP; 2011 Jul; 12(4):425-8. PubMed ID: 21737909
[TBL] [Abstract][Full Text] [Related]
15. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping.
Arts J; Caenepeel P; Bisschops R; Dewulf D; Holvoet L; Piessevaux H; Bourgeois S; Sifrim D; Janssens J; Tack J
Clin Gastroenterol Hepatol; 2009 Apr; 7(4):432-7. PubMed ID: 19264574
[TBL] [Abstract][Full Text] [Related]
17. Octreotide therapy in dumping syndrome: Analysis of long-term results.
Didden P; Penning C; Masclee AA
Aliment Pharmacol Ther; 2006 Nov; 24(9):1367-75. PubMed ID: 17059518
[TBL] [Abstract][Full Text] [Related]
18. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis.
Safdi M; Bekal PK; Martin S; Saeed ZA; Burton F; Toskes PP
Pancreas; 2006 Aug; 33(2):156-62. PubMed ID: 16868481
[TBL] [Abstract][Full Text] [Related]
19. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
[TBL] [Abstract][Full Text] [Related]
20. Long-acting octreotide in the treatment of diarrhea after pelvic pouch surgery.
Gullichsen R
Tech Coloproctol; 2006 Dec; 10(4):346-9. PubMed ID: 17115310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
